Dublin, Aug. 23, 2024 (GLOBE NEWSWIRE) -- The "Retinoblastoma Treatment Market Report, Global, 2024" report has been added to ResearchAndMarkets.com's offering.
Market Growth Trajectory
Global retinoblastoma treatment market is projected to expand from $1.93 billion in 2023 to $2.03 billion in 2024, demonstrating a compound annual growth rate (CAGR) of 5.5%. This growth is underpinned by an array of factors, including increased levels of funding, heightened awareness of cancer types, and significant strides in cancer research. The market is further anticipated to reach a valuation of $2.56 billion by 2028, growing at a CAGR of 5.9%.
Several key elements are propelling the retinoblastoma treatment market forward. These include soaring demand for ophthalmic treatment and surgeries, growing incidences of retinoblastoma, and expanding research and development initiatives. Furthermore, technological advancements in medicine are enhancing diagnostic capabilities, while increased investments in pediatric oncology and new product approvals are setting the stage for immense growth within this sector. Pharmaceutical companies are actively pursuing innovative therapeutic solutions, such as oncolytic adenovirus treatments, to address the crucial needs presented by this rare childhood cancer.
Innovation and Acquisitions
In a display of commitment to innovation, key market players are focusing their efforts on emerging treatments that promise greater effectiveness and specificity in targeting cancer cells. The acquisition of VCN Biosciences S.L. by Synthetic Biologics Inc. underscores the dynamic nature of the market, with VCN-01, an oncolytic adenovirus therapy, showing promise in clinical trials for treating retinoblastoma.
Regional Market Insights
North America emerged as the largest contributor to the retinoblastoma treatment market in 2023. Meanwhile, Asia-Pacific is forecasted to experience the fastest growth during the upcoming period. Market expansion in these regions is fueled by advancements in healthcare infrastructure, rising medical expenditure, and increasing public awareness regarding eye health and cancer treatment.
About the Retinoblastoma Treatment Market
Retinoblastoma treatment encompasses a broad range of medical procedures and therapies aimed at combating this rare ocular malignancy, most prevalent among young children. With the primary goal of eradicating the cancer, preserving vision, and mitigating recurrence risk, treatment modalities include surgery, radiation, and various chemotherapy techniques administered across specialized hospitals and cancer institutes. Major entities in the market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., and Sanofi S.A., among others, signifying a competitive and diverse landscape.
This report offers an exhaustive analysis of the retinoblastoma treatment market, furnishing stakeholders with invaluable insights into the current and future outlook of this niche yet vital healthcare arena. The comprehensive data outlined in the report reflects on the revenue generated from services encompassing multidisciplinary care, genetic counseling, and patient monitoring, as well as the sales of targeted therapies and chemotherapy injections. It underscores the significance of the value provided by manufacturers and service providers within the retinoblastoma treatment domain.
The report captures the essence of market dynamics, offering a strategic overview essential for anyone looking to understand the retinoblastoma treatment market's trajectory.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 175 |
| Forecast Period | 2024 - 2028 |
| Estimated Market Value (USD) in 2024 | $2.03 Billion |
| Forecasted Market Value (USD) by 2028 | $2.56 Billion |
| Compound Annual Growth Rate | 5.9% |
| Regions Covered | Global |
Companies Featured
- Johnson & Johnson Services Inc.
- F. Hoffmann-La Roche AG
- Merck & Co. Inc.
- Sanofi S.A.
- Bristol-Myers Squibb Company
- Novartis AG
- Pfizer Inc.
- GlaxoSmithKline Plc
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Company
- Teva Pharmaceutical Industries Ltd.
- Baxter International Inc.
- Regeneron Pharmaceuticals Inc.
- Astellas Pharma Inc.
- Otsuka Pharmaceutical
- Daiichi Sankyo Company
- Taiho Pharmaceutical Co. Ltd.
- Icon Bioscience Inc.
- Ono Pharmaceutical Co. Ltd.
- Nippon Shinyaku Co. Ltd.
- Cadila Pharmaceuticals
- Arcus Biosciences Inc.
- Sheba Medical Center
- Cellceutix Corporation
- Phio Pharmaceuticals Inc.
For more information about this report visit https://www.researchandmarkets.com/r/3z7lla
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
